THERAFLU WARMING RELIEF COLD AND CHEST CONGESTION OTC
Generic Name and Formulations:
Acetaminophen 325mg, guaifenesin 200mg, phenylephrine HCl 5mg; per 15mL; liq; contains potassium 5mg/15mL, sodium 9mg/15mL; orange flavor.
Novartis Consumer Health
Indications for THERAFLU WARMING RELIEF COLD AND CHEST CONGESTION:
Minor aches and pains. Headache. Fever. Nasal and sinus congestion. Chest congestion.
30mL every 4 hours. Max 180mL/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Liver disease. Heart disease. Hypertension. Thyroid disease. Diabetes. COPD. Asthma. GI or GU obstruction. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effect of sympathomimetics. Antagonizes antihypertensives.
Analgesic + expectorant + sympathomimetic.
Nervousness, dizziness, insomnia; hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation